Device Devices

Gore Excluder Thoracoabdominal Branch Endoprosthesis

Payments companies reported to CMS as associated with Gore Excluder Thoracoabdominal Branch Endoprosthesis. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.2Massociated payments (2023-2025)
2,034clinicians with associated payments
1company reporting

By year

2024 $415K
2025 $735K

Payments reported as associated with Gore Excluder Thoracoabdominal Branch Endoprosthesis, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Vascular Surgery $998K
Surgery $60K
Thoracic Surgery (Cardiothoracic Vascular Surgery) $29K
Vascular & Interventional Radiology $13K
Physician Assistant $7,154
Interventional Cardiology $5,096

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Gore Excluder Thoracoabdominal Branch Endoprosthesis

These are the largest totals companies reported as associated with Gore Excluder Thoracoabdominal Branch Endoprosthesis. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Jason Lee Palo Alto, CA Vascular Surgery $75,983.04
Sukgu Han Los Angeles, CA Vascular Surgery $53,668.75
Luis Sanchez Saint Louis, MO Vascular Surgery $51,772.99
Evan Brownie Murray, UT Vascular Surgery $31,690.92
K Dean Arnaoutakis Tampa, FL Vascular Surgery $19,432.35
John Ohman Saint Louis, MO Vascular Surgery $18,400.49
Michel Makaroun Pittsburgh, PA Vascular Surgery $17,175.94
Dai Yamanouchi Madison, WI Vascular Surgery $16,160.79
Hasan Aldailami Scottsdale, AZ Vascular Surgery $11,394.33
Frank Arko Charlotte, NC Vascular Surgery $9,273.77

Prescribed Gore Excluder Thoracoabdominal Branch Endoprosthesis?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.